Landgren, C. O. Et Al. 2020. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). LEUKEMIA , vol.34, no.7 , 1840-1852.

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., ... Sandhu, I.(2020). Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). LEUKEMIA , vol.34, no.7, 1840-1852.

Landgren, C. Et Al. "Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)," LEUKEMIA , vol.34, no.7, 1840-1852, 2020

Landgren, C. O. Et Al. "Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)." LEUKEMIA , vol.34, no.7, pp.1840-1852, 2020

Landgren, C. O. Et Al. (2020) . "Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)." LEUKEMIA , vol.34, no.7, pp.1840-1852.

@article{article, author={C. Ola Landgren Et Al. }, title={Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)}, journal={LEUKEMIA}, year=2020, pages={1840-1852} }